Current Funding Opportunities
- External Funding
- Internal Grant Opportunities
The fund will facilitate the advancement of innovative basic science, translational or clinical research to advance the understanding and treatment of Myelodysplastic Syndromes (MDS) and related blood disorders (such as MDS/myeloproliferative neoplasms (MPN) overlap syndromes, secondary acute myeloid leukemia following MDS, idiopathic cytopenia of undetermined significance (ICUS), or clonal hematopoiesis of indeterminate potential (CHIP).
The foundation will consider proposals from individuals at university, college, hospital, or laboratory institutions for support of research in MDS or related disorders in two types:
- Early Career Awards
- Established Investigator Awards
Letter of Intent (LOI) Deadline: LOIs are accepted on a rolling basis.
Fast Funding for COVID-19 Science
If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant.
Deadline: Fast Grant decisions are made in under 48 hours. Apply Now!
- Breast Cancer, Breakthrough Award Levels 1 and 2 - Application Deadline - March 11, 2021
- Breast Cancer, Era of Hope Scholar Award - Application Deadline: March 11, 2021
- Breast Cancer, Transformative Breast Cancer Consortium Award - Application Deadline: March 12, 2021
- Breast Cancer, Innovator Award - Application Deadline: March 12, 2021
- Breast Cancer, Breakthrough Award Level 3 - Application Deadline: March 12, 2021
- Breast Cancer, Breakthrough Award Level 4 - Application Deadline: March 12, 2021
- SITC–Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship (two years, $200,000)
- SITC–Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship (one year, $100,000)
- SITC–AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship (one year, $100,000)
- SITC–Nektar Therapeutics Equity and Inclusion in Cancer Immunotherapy Fellowship (one year, $50,000)